• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

[BMJ] Tranexamic acid reduces mortality in traumatic bleeding

bys25qthea
September 14, 2012
in Cardiology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC

Key findings:

  1. Tranexamic acid was found to significantly reduce all cause mortality in patients with traumatic bleeding, except in those with the lowest baseline risk of death
  2. Tranexamic acid was found to be associated with reduced odds of thromboembolic events in patients with traumatic bleeding

Primer: Tranexamic acid is a synthetic derivative of lysine that is used to manage or prevent excessive bleeding, by inhibiting the formation of plasmin. In the CRASH-2 trial, it was shown that a short course of tranexamic acid administered within three hours of injury to adults with traumatic bleeding reduced all-cause mortality and demonstrated no significant increase in thromboembolic risk. What is not known, however, is how the effects of tranexamic acid change with the baseline risk of death. Do patients with traumatic bleeding and a higher risk of dying at baseline experience greater benefits with tranexamic acid treatment than those with lower risk?

This [randomized] study: Published recently in BMJ, a study sought to answer this question by conducting a prespecified analysis on data collected during the CRASH-2 trial, a randomised controlled trial comparing tranexamic acid with placebo. The purpose of the study was to explore how the effects of tranexamic acid differ according to the baseline risk of death in patients suffering traumatic bleeding. Using a previously developed prognostic model, patients from the CRASH-2 trial who started treatment within three hours of injury were classified into one of four risk strata of mortality: <6%, 6-20%, 21-50%, and >50%. The effect of a specific regimen of tranexamic acid (1 g over 10 minutes, then 1 g over eight hours) on all cause mortality, deaths from bleeding, and thromboembolic events was compared with placebo in each strata.

The analysis involved 13,273 patients. Except for the lowest risk strata (i.e., <6%), tranexamic acid was associated with significantly lower odds of mortality compared to placebo. The odds ratio for deaths from all causes was 0.83 (95% CI 0.70-1.00) for the 6-20% risk of baseline mortality stratum, 0.80 (95% CI 0.69-0.94) for 21-50%, and 0.77 (95% CI 0.68-0.87) for >50%, all in favour of tranexamic acid treatment. The study also found that tranexamic acid was associated with significant reductions in the risk of fatal and non-fatal thromboembolic events (OR 0.69; 95% CI 0.53-0.89).

In sum: In patients with traumatic bleeding, reductions in all-cause mortality and deaths from bleeding did not significantly differ according to baseline risk of mortality. By using tranexamic acid, the odds of death from bleeding in each of the risk strata and odds of thromboembolic events were both reduced by approximately 30%. Thus, these data demonstrate that tranexamic acid use should not be restricted to patients with severe bleeding, though the benefit in low risk patients was not significant. The strength of the study was that the data examined were obtained from a large, randomised controlled trial with adequate allocation concealment and blinding, and low loss to follow-up. Weaknesses of the study include inaccuracy in establishing cause of death in trauma patients and inaccuracy in the diagnosis of non-fatal events.

Click to read in BMJ

RELATED REPORTS

Higher body mass index may be associated with altered vitamin D levels and metabolism

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

Community-based adult vision screening program increases access to eye care

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCALIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

Previous Post

[JAMA] Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events

Next Post

[CMAJ] Influenza vaccination coverage across ethnic groups

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Chronic Disease

Higher body mass index may be associated with altered vitamin D levels and metabolism

January 27, 2023
#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
StudyGraphics

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

January 27, 2023
Roux-en-Y gastric bypass may slow progression of diabetic retinopathy
Ophthalmology

Community-based adult vision screening program increases access to eye care

January 27, 2023
Fracture severity associated with treatment invasiveness for distal radius fractures
Cardiology

Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures

January 27, 2023
Next Post

[CMAJ] Influenza vaccination coverage across ethnic groups

Pertussis outbreaks on the rise, vaccine effectiveness waning [NEJM]

Minor Strokes, TIAs increase risk of disability [Stroke]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options